These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 30883839)
1. Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis. Hermann R; Litwin JS; Friberg LE; Dangond F; Munafo A Br J Clin Pharmacol; 2019 Jul; 85(7):1484-1494. PubMed ID: 30883839 [TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Cook S; Vermersch P; Comi G; Giovannoni G; Rammohan K; Rieckmann P; Sørensen PS; Hamlett A; Miret M; Weiner J; Viglietta V; Musch B; Greenberg SJ; Mult Scler; 2011 May; 17(5):578-93. PubMed ID: 21228029 [TBL] [Abstract][Full Text] [Related]
3. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis. Cook S; Leist T; Comi G; Montalban X; Giovannoni G; Nolting A; Hicking C; Galazka A; Sylvester E Mult Scler Relat Disord; 2019 Apr; 29():157-167. PubMed ID: 30885374 [TBL] [Abstract][Full Text] [Related]
4. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study. Ali S; Paracha N; Cook S; Giovannoni G; Comi G; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Greenberg S; Scott DA; Joyeux A; Clin Drug Investig; 2012 Jan; 32(1):15-27. PubMed ID: 22017519 [TBL] [Abstract][Full Text] [Related]
5. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Comi G; Cook S; Giovannoni G; Rieckmann P; Sørensen PS; Vermersch P; Galazka A; Nolting A; Hicking C; Dangond F Mult Scler Relat Disord; 2019 Apr; 29():168-174. PubMed ID: 30885375 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan KW; Rieckmann P; Comi G; Dangond F; Hicking C; Vermersch P Mult Scler; 2019 May; 25(6):819-827. PubMed ID: 29716436 [TBL] [Abstract][Full Text] [Related]
7. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S; Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565 [TBL] [Abstract][Full Text] [Related]
8. Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study. Gorrod HB; Latimer NR; Damian D; Hettle R; Harty GT; Wong SL Value Health; 2019 Jul; 22(7):772-776. PubMed ID: 31277823 [TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan K; Rieckmann P; Comi G; Dangond F; Adeniji AK; Vermersch P Mult Scler; 2018 Oct; 24(12):1594-1604. PubMed ID: 28870107 [TBL] [Abstract][Full Text] [Related]
10. Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands. Michels RE; de Fransesco M; Mahajan K; Hengstman GJD; Schiffers KMH; Budhia S; Harty G; Krol M Appl Health Econ Health Policy; 2019 Dec; 17(6):857-873. PubMed ID: 31444659 [TBL] [Abstract][Full Text] [Related]
11. Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods. Bell Gorrod H; Latimer NR; Damian D; Hettle R; Harty GT; Wong SL Adv Ther; 2020 Jan; 37(1):225-239. PubMed ID: 31701485 [TBL] [Abstract][Full Text] [Related]
12. Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Lambe T; Duarte R; Mahon J; Nevitt S; Greenhalgh J; Boland A; Beale S; Kotas E; McEntee J; Pomeroy I Pharmacoeconomics; 2019 Mar; 37(3):345-357. PubMed ID: 30328051 [TBL] [Abstract][Full Text] [Related]
13. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis. Brochet B; Hupperts R; Langdon D; Solari A; Piehl F; Lechner-Scott J; Montalban X; Selmaj K; Valis M; Rejdak K; Havrdova EK; Patti F; Alexandri N; Nolting A; Keller B Mult Scler Relat Disord; 2022 Jan; 57():103385. PubMed ID: 35158476 [TBL] [Abstract][Full Text] [Related]
14. The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis. Hermann R; Karlsson MO; Novakovic AM; Terranova N; Fluck M; Munafo A Clin Pharmacokinet; 2019 Mar; 58(3):283-297. PubMed ID: 29987837 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England. Hettle R; Harty G; Wong SL J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal. Pinheiro B; Guerreiro R; Costa J; Miguel LS J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777 [No Abstract] [Full Text] [Related]
18. Evaluation of therapy satisfaction with cladribine tablets in patients with RMS: Final results of the non-interventional study CLEVER. Ziemssen T; Posevitz-Fejfár A; Chudecka A; Cepek L; Reifschneider G; Grothe C; Richter J; Wagner T; Müller B; Penner IK Mult Scler Relat Disord; 2024 Oct; 90():105812. PubMed ID: 39151238 [TBL] [Abstract][Full Text] [Related]
19. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Leist T; Cook S; Comi G; Montalban X; Giovannoni G; Nolting A; Damian D; Syed S; Galazka A Mult Scler Relat Disord; 2020 Nov; 46():102572. PubMed ID: 33296971 [TBL] [Abstract][Full Text] [Related]